Tyme Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Companyâs therapeutic approach is designed to take advantage of a cancer cellâs innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the bodyâs immune system. Source
No articles found.
Connectyx Technologies Holdings Group, Inc. provides products in the healthcare ma...
Connectyx Technologies Holdings Group, Inc. pro...
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
We are a profitable and growing company focused on the acquisition, development an...
We are a profitable and growing company focused...
We are a clinical-stage immuno-oncology company specializing in the development an...
We are a clinical-stage immuno-oncology company...
Intercept is a biopharmaceutical company focused on the development and commercial...
Intercept is a biopharmaceutical company focuse...
Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focuse...
Stemline Therapeutics, Inc. is a commercial-sta...
Join the National Investor Network and get the latest information with your interests in mind.